Given the critical oncogenic role of SOX9 and the high frequency of KEAP1 mutations in lung carcinoma and HCC, our study suggests an optimal treatment strategy based on genetic status, which may provide stratified clinical treatments for individual lung carcinoma or HCC patients. This evidence concerns the gene KEAP1 and hepatocellular carcinoma.